TDSGF (Telo Genomics) Cyclically Adjusted Book per Share: $0.06 (As of Mar. 2026)


What is Telo Genomics Cyclically Adjusted Book per Share?

Telo Genomics TDSGF -27.59% Cyclically Adjusted Book per Share is $0.06 as of Mar. 2026. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Telo Genomics's adjusted book value per share for the three months ended in Mar. 2026 was $-0.007. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.06 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Telo Genomics's average Cyclically Adjusted Book Growth Rate was -28.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -23.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Telo Genomics was -23.90% per year. The lowest was -23.90% per year. And the median was -23.90% per year.

As of today (2026-07-01), Telo Genomics's current stock price is $0.0231. Telo Genomics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $0.06. Telo Genomics's Cyclically Adjusted PB Ratio of today is 0.39.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Telo Genomics was 0.43. The lowest was 0.00. And the median was 0.00.


Telo Genomics  (OTCPK:TDSGF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Telo Genomics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.0231/0.06
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Telo Genomics was 0.43. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Telo Genomics Cyclically Adjusted Book per Share Related Terms


Telo Genomics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Telo Genomics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telo Genomics Cyclically Adjusted Book per Share Chart

Telo Genomics Annual Data
Trend Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.27 0.19 0.18 0.09

Telo Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.09 0.00 0.11 0.06

TDSGF vs TMO, DHR, IDXX: Cyclically Adjusted Book per Share Comparison

For the Diagnostics & Research subindustry, Telo Genomics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Cyclically Adjusted PB Ratio falls into.



Telo Genomics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Telo Genomics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.007/132.2623*132.2623
=-0.007

Current CPI (Mar. 2026) = 132.2623.

Telo Genomics Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.392 102.002 0.508
201609 0.323 101.765 0.420
201612 0.453 101.449 0.591
201703 0.328 102.634 0.423
201706 0.157 103.029 0.202
201709 0.090 103.345 0.115
201712 0.104 103.345 0.133
201803 0.056 105.004 0.071
201806 -0.019 105.557 -0.024
201809 -0.033 105.636 -0.041
201812 -0.041 105.399 -0.051
201903 -0.047 106.979 -0.058
201906 -0.059 107.690 -0.072
201909 -0.067 107.611 -0.082
201912 0.022 107.769 0.027
202003 0.017 107.927 0.021
202006 0.014 108.401 0.017
202009 0.013 108.164 0.016
202012 0.026 108.559 0.032
202103 0.030 110.298 0.036
202106 0.054 111.720 0.064
202109 0.051 112.905 0.060
202112 0.048 113.774 0.056
202203 0.043 117.646 0.048
202206 0.034 120.806 0.037
202209 0.026 120.648 0.029
202212 0.018 120.964 0.020
202303 0.010 122.702 0.011
202306 0.028 124.203 0.030
202309 0.021 125.230 0.022
202312 0.013 125.072 0.014
202403 0.006 126.258 0.006
202406 0.006 127.522 0.006
202409 0.000 127.285 0.000
202412 0.012 127.364 0.012
202503 0.008 129.181 0.008
202506 0.004 129.892 0.004
202509 0.000 130.287 0.000
202512 -0.004 130.366 -0.004
202603 -0.007 132.262 -0.007

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $0.06 mean?
Telo Genomics (TDSGF) has a Cyclically Adjusted Book per Share of $0.06 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Telo Genomics and its competitors.
Is Telo Genomics' Cyclically Adjusted Book per Share too high?
Telo Genomics' current Cyclically Adjusted Book per Share is $0.06.
How does Telo Genomics' Cyclically Adjusted Book per Share compare to TMO and DHR?
Telo Genomics' Cyclically Adjusted Book per Share of $0.06 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Book per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Telo Genomics and its competitors. Telo Genomics's current Cyclically Adjusted Book per Share is $0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telo Genomics stock overvalued right now?
Telo Genomics (TDSGF) has a current Cyclically Adjusted Book per Share of $0.06. The current Cyclically Adjusted Book per Share is $0.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Telo Genomics (TDSGF), the current Cyclically Adjusted Book per Share is $0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Telo Genomics Business Description

Other Exchanges 3D0A:GermanyTELO:Canada
Address 2255 York Avenue, Suite 203, Vancouver, BC, CAN, V6K 1C5
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.